**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number

10/665,005

Filing Date

09/19/2003

First Named Inventor

Kamil Paruch

Art Unit

Examiner Name

Attorney Docket Number

OC01625K

**ENCLOSURES (Check all that apply)**

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Response to Missing Parts/  
Incomplete ApplicationResponse to Missing Parts  
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a  
Provisional Application

Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_

Remarks

After Allowance Communication  
to GroupAppeal Communication to Board  
of Appeals and InterferencesAppeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please  
Identify below):

Cert. of Mailing - 1pg.; References (9);

PTO-1449 Form-1pg. in dup.; Post Card

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**Firm  
or

Individual

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Signature

Date

12/11/2003

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: \_\_\_\_\_


Typed or printed

Signature

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Attorney Docket No.: OC01625K

PTO/SB/92 (08-03)

(Modified)

Application No.: 10/665,005

Filing Date: 09/19/2003

Applicant: Kamil Paruch et al.

Title: NOVEL IMIDAZOPYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS

### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 12/11/2003  
Date

Signature

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Typed or printed name of person signing Certificate

**Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.**

Documents enclosed:

Response Transmittal (PTO/SB/21) - 1pg.

Information Disclosure Statement - 2pgs.

PTO-1449 Form - 1pg. in duplicate

References (9)

Certificate of Mailing - 1pg.

Post Card

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

\_\_\_\_\_  
X  
Applicant(s): **Kamil Paruch et al.** : Group Art Unit:  
Serial No.: **10/666,005** : Examiner:  
Filed: **09/19/2003** : Attorney Docket No. : **OC01625K**  
For: **"Novel Imidazopyrazines as  
Cyclin Dependent Kinase  
Inhibitors"** :  
\_\_\_\_\_  
X

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) \_\_\_\_\_ filed \_\_\_\_\_, respectively.

(b) No fee is believed due because:

- ☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ This Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

- (c) ☐ This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
  - ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- (d) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- ☐ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0395, Patent Case No. OC01625K. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
SCHERING-PLOUGH CORPORATION

Dated: 12/11/2003  
SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

By: 

Name: **Palaiyur S. Kalyanaraman**  
Reg. No.: **34,634**  
**Attorney of Record**  
Telephone No.: (908) 298-5068

Sheet 1 of 1

|   |    |  |            |  |       |                                       |                               |
|---|----|--|------------|--|-------|---------------------------------------|-------------------------------|
| FORM P-1449   |    | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE   |            | ATTY. DOCKET NO.:<br><b>OC01625K</b>     |       | APPLICATION NO.:<br><b>10/665,005</b> |                               |
| INFORMATION DISCLOSURE STATEMENT<br>BY APPLICANT<br><br>(Use several sheets if necessary)   |    |  |            | APPLICANT:<br><b>Kamil Paruch et al.</b> |       |                                       |                               |
|   |    |  |            | FILING DATE:<br><b>09/19/2003</b>        |       | GROUP:                                |                               |
| U.S. PATENT DOCUMENTS   |    |  |            |  |       |                                       |                               |
| *EXAMINER<br>INITIAL  |    | DOCUMENT<br>NUMBER   | DATE       | NAME                                     | CLASS | SUB-<br>CLASS                         | FILING DATE IF<br>APPROPRIATE |
|   | AA |  |            |  |       |                                       |                               |
|   | AB |  |            |  |       |                                       |                               |
|   | AC |  |            |  |       |                                       |                               |
|   | AD |  |            |  |       |                                       |                               |
|   | AE |  |            |  |       |                                       |                               |
|   | AF |  |            |  |       |                                       |                               |
|   | AG |  |            |  |       |                                       |                               |
|   | AH |  |            |  |       |                                       |                               |
|   | AI |  |            |  |       |                                       |                               |
|   | AJ |  |            |  |       |                                       |                               |
|   | AK |  |            |  |       |                                       |                               |
| FOREIGN PATENT DOCUMENTS  |    |  |            |  |       |                                       |                               |
|   |    | DOCUMENT<br>NUMBER   | DATE       | COUNTRY                                  | CLASS | SUB-<br>CLASS                         | TRANSLATION<br>YES NO         |
| ✓   | AL | EP 0 778 277   | 06/11/1997 | EPO                                      |       |                                       |                               |
| ✓   | AM | WO 02/06286  | 01/24/2002 | PCT                                      |       |                                       |                               |
| ✓   | AN | WO 88/04298  | 06/16/1988 | PCT                                      |       |                                       |                               |
|   | AO |  |            |  |       |                                       |                               |
|   | AP |  |            |  |       |                                       |                               |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  |    |  |            |  |       |                                       |                               |
| ✓   | AQ | Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), <b>224</b> : 771-786.  |            |  |       |                                       |                               |
| ✓   | AR | Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients With Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), <b>16</b> (9): 2986-2999. |            |  |       |                                       |                               |
| ✓   | AS | Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), <b>243</b> : 527-536.                              |            |  |       |                                       |                               |
| ✓   | AT | Bible et al., "Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), <b>57</b> : 3375-3380.            |            |  |       |                                       |                               |
| ✓   | AU | Shiota et al., "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5α]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), <b>47</b> (7): 928-938.             |            |  |       |                                       |                               |
| ✓   | AV | Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines.", <i>Chem. Pharm. Bull.</i> (1962), <b>10</b> : 620-626.   |            |  |       |                                       |                               |
| EXAMINER  |    |  |            | DATE CONSIDERED                          |       |                                       |                               |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |    |  |            |  |       |                                       |                               |